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Background: Plaque psoriasis is a debilitating skin condition that affects approximately 2% of the adult population
and for which there is currently no cure. Tofacitinib is an oral Janus kinase inhibitor that is being investigated for
psoriasis.
Methods: The design of this study has been reported previously (NCT00678210). Patients with moderate to severe
chronic plaque psoriasis received tofacitinib (2 mg, 5 mg, or 15 mg) or placebo, twice daily, for 12 weeks.
Lymphocyte sub-populations, cytomegalovirus (CMV) and Epstein-Barr virus (EBV) DNA were measured at baseline
and up to Week 12.
Results: Tofacitinib was associated with modest, dose-dependent percentage increases from baseline in median B
cell count at Week 4 (24–68%) and Week 12 (18–43%) and percentage reductions from baseline in median natural
killer cell count at Week 4 (11–40%). The proportion of patients with detectable CMV and EBV DNA (defined as
>0 copies/500 ng total DNA) increased post-baseline in tofacitinib-treated patients. However, multivariate analyses
found no relationship between changes in CMV or EBV viral load and changes in lymphocyte sub-populations or
tofacitinib treatment.
Conclusions: Twelve weeks of treatment with tofacitinib had no clinically significant effects on CMV or EBV viral load,
suggesting that lymphocyte sub-populations critical to the response to chronic viral infections and viral reactivation
were not significantly affected. Replication of these findings during long-term use of tofacitinib will allow confirmation
of this observation.
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Psoriasis is a debilitating and recurring immune-mediated
inflammatory disease that affects 0.91–8.5% of the adult
population according to geographic region [1]. Plaque
psoriasis is by far the most prevalent form, accounting for
approximately 80% of cases [2]. Tofacitinib is an oral Janus
kinase (JAK) inhibitor that is being investigated for psoria-
sis. Oral tofacitinib has been evaluated in a Phase I study* Correspondence: hernan.valdez@pfizer.com
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unless otherwise stated.in patients with active psoriasis [3], and in Phase II and
Phase III studies in patients with chronic plaque psoriasis
[4-6] (see also NCT01276639 and NCT01309737). Tofaci-
tinib binds to and inhibits JAK1 and JAK3, thereby block-
ing pro-inflammatory cytokine signaling, in particular
interleukin (IL)-6 and interferon γ [7,8]. C-reactive protein
(CRP), a marker of inflammation, is under the transcrip-
tional control of IL-6 [9] and, thus, may be modulated by
tofacitinib. Tofacitinib also modulates the activity of sev-
eral other interleukins (including IL-2, −4, −7, −9, −15,
and −21) that have roles in mediating immune response to
viral infection/reactivation, lymphocyte development, and
effector function [10,11]. Owing to the chronic nature oftral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Valenzuela et al. BMC Dermatology  (2015) 15:8 Page 2 of 11psoriasis and consequent prolonged and repeated periods
of exposure to systemic immunomodulatory therapies, it
is important to evaluate the potential effects of new ther-
apies, such as tofacitinib, on immunosurveillance.
This exploratory analysis investigated the effect of oral
tofacitinib on lymphocyte sub-populations to identify
any impact of tofacitinib on immunosurveillance during
a Phase IIb, 12-week, placebo-controlled study in pa-
tients with moderate to severe plaque psoriasis [4]. The
potential for reactivation of latent viruses (eg cyto-
megalovirus [CMV], John Cunningham virus, Epstein-
Barr virus [EBV], hepatitis B virus, and varicella zoster
virus) has been described with other immunosuppressive
agents [12-17]. Recurrence of CMV infection in im-
munocompromised patients can cause damage to the di-
gestive system, lungs, and eyes [18]. CMV infections
have been reported in patients with psoriasis receiving
biologic therapies including the tumor necrosis factor
inhibitor (TNFi) etanercept, and efalizumab, an anti-
CD11a antibody [12,13]. Efalizumab was found to be as-
sociated with increased risk of John Cunningham virus
-related progressive multifocal leukoencephalopathy, a
potentially fatal infection of the central nervous system
and, consequently, was withdrawn from the market in
2009 [19]. Reactivation of EBV is associated with devel-
opment of lymphoproliferative malignancies including
non-Hodgkin lymphoma, and has been reported in pa-
tients receiving biologic and nonbiologic treatment for
psoriasis [14,15]. Reactivation of hepatitis B virus can
lead to severe hepatitis, liver failure, and death [20]. A
need for hepatitis B virus screening and pre-emptive
therapy has been highlighted in patients receiving TNFi
therapy [21]. Reactivation of latent varicella zoster virus
causes shingles, the main complication of which is
chronic pain, and is a long-term challenge in patients re-
ceiving immunosuppressive therapy [17].
In the present study, potential for viral reactivation in
general was evaluated using CMV and EBV DNA copy
numbers as surrogates of viral-specific immune surveil-
lance. To complement evaluation of lymphocyte sub-
populations during tofacitinib treatment, changes in
inflammatory activity during tofacitinib treatment were
assessed using serum levels of CRP as a marker.
Methods
This was a Phase IIb, randomized, double-blind, parallel-
group, placebo-controlled study conducted in 42 centers
in the United States and Canada (NCT00678210). Pa-
tients were aged ≥18 years with moderate to severe
chronic plaque-type psoriasis covering ≥15% of the total
body surface area, had stable disease for ≥6 months, a
Psoriasis Area and Severity Index (PASI) score ≥13 and
were eligible for phototherapy or systemic treatment of
psoriasis [4]. Patients were excluded if they had receivedany prior lymphocyte-depleting therapy (eg alemtuzu-
mab, cyclophosphamide, chlorambucil) or had received
rituximab/other selective B lymphocyte-depleting ther-
apy within the preceding 12 months.
The study design has been reported elsewhere [4].
Briefly, patients were randomized 1:1:1:1 to receive oral
tofacitinib (2 mg, 5 mg, or 15 mg twice daily [BID]), or
placebo, for 12 weeks. Follow-up continued for 4 weeks
after study completion or withdrawal. The safety popula-
tion (all patients who received at least one dose of tofa-
citinib or placebo) was used in this exploratory analysis.
The study was performed in compliance with the Inter-
national Conference on Harmonization Good Clinical
Practice Guidelines. All patients provided written in-
formed consent, and both consent documentation and
the final protocol were reviewed and approved by the in-
stitutional review board and/or the independent ethics
committee at each of the investigational centers partici-
pating in the study.
Cell and viral quantification
Whole blood and serum were collected and analyzed.
Lymphocyte populations were identified and quantified by
fluorescence-activated cell sorting (FACS) analysis at base-
line, Weeks 4 and 12, or early termination. Lymphocyte
subset markers analyzed included: CD3+ (total T cells),
CD3+/CD4+ (T helper cells; TH), CD3
+/CD8+ (cytotoxic
T cells; TC), CD19
+ (B cells), and CD16+/CD56+ (natural
killer cells; NK).
Serum CRP levels were measured at baseline and Week
12 or early termination. Blood CMV and EBV DNA was
measured at baseline, Weeks 4 and 8 (CMV only), and
Week 12 or early termination. Viral loads were quantified
by real-time polymerase chain reaction (PCR) using DNA
isolated directly from peripheral blood leukocytes and
expressed as viral DNA copies/500 ng of total DNA. CMV
or EBV DNA levels >0 copies/500 ng total DNA were de-
fined as detectable.
Statistical analysis
For continuous endpoints measured longitudinally, a re-
peated mixed-effect model was used to analyze change
from baseline, where treatment, visit week, and inter-
action between treatment and visit week were included
as fixed factors, along with baseline value as the covari-
ate. For continuous endpoints evaluated at a single time
point, analysis of covariance (ANCOVA) was used to
analyze change from baseline, and the baseline value
was included as covariate. For categorical data, compari-
sons between groups were performed using a Chi-
squared test. Missing values were not imputed in any of
these analyses.
Spearman’s correlation analyses, based on the ranks of
variables, were performed between change in viral load
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cell counts. A linear model was used to assess potential
relationships between change in viral load or CRP level,
and change in lymphocyte sub-population cell counts,
and doses of tofacitinib.
Results
Baseline demographics, disease characteristics, and la-
boratory values (including lymphocyte sub-population
cell counts, CRP, CMV, and EBV viral load) were similar
between groups (Table 1).
Effects on T cells
In patients receiving tofacitinib, there was a dose-
dependent percentage increase from baseline in median
total T (CD3+) cell count at Week 4, returning to near
baseline levels by Week 12 (Table 2, Figure 1). Such a
trend was not observed in patients receiving placebo.
A similar pattern of dose-dependent percentage increases
at Week 4, followed by a return to near baseline levels at
Week 12, was observed in median TH (CD3
+/CD4+) cell
counts (Table 2, Figure 1). No patient had a TH cell
count <200 cells/mm3. Among patients with a TH cell
count of ≥500 cells/mm3 at baseline (n = 170), two, two,
one, and three patients receiving placebo, tofacitinib 2 mg,
5 mg, or 15 mg BID, respectively, had a single post-baselineTable 1 Patient demographics, disease characteristics, cell co
Placebo
(n = 50)
Mean age, years (SD) 43.9 (13.0)
Male, n (%) 36 (72.0)
White, n (%) 41 (82.0)
Mean weight, kg (SD) 89.6 (23.9)
Mean PASI score (SD) 21.5 (7.1)





Median cell counts, cells/mm3 (Q25, Q75):
T (CD3+) 1310 (982, 1517)
TH (CD3
+/CD4+) 802 (615, 975)
TC (CD3
+/CD8+) 431 (287, 570)
B (CD19+) 195 (134, 304)
NK (CD16+/CD56+) 159 (93, 188)
Median CMV viral load, copies/500 ng total DNA (Q25, Q75) 0 (0.00, 0.00)
Median EBV viral load, copies/500 ng total DNA (Q25, Q75) 0 (0.00, 1.30)
Median CRP, mg/L (Q25, Q75) 1.84 (0.83, 4.41)
B, B cells; BSA, body surface area; BID, twice daily; CMV, cytomegalovirus; CRP, C-rea
NK, natural killer cells; PASI, Psoriasis Area and Severity Index; PGA, Physician’s Glob
SD, standard deviation; T, total T cells; TC, cytotoxic T cells; TH, T helper cells.measurement of <500 cells/mm3. Only one patient had
two consecutive TH cell counts <500 cells/mm
3 (Week 4
and Week 12). This patient received tofacitinib 2 mg BID.
While there was some variability in TC (CD3
+/CD8+) cell
counts, these changes did not appear to be dose
dependent (Table 2, Figure 1).
Overall, there was a good correlation between total
lymphocyte count and sub-population cell counts (T
cells, TH cells, and TC cells) across groups, ranging from
0.62–0.93 at baseline, 0.58–0.94 at Week 4, and 0.56–
0.92 at Week 12.
Effects on B cells
Tofacitinib treatment resulted in dose-dependent percent-
age increases from baseline in B cell counts that were sus-
tained throughout the study (Table 2, Figure 1). At Week
12, five (13.2%), two (5.4%), and four (10.3%) patients re-
ceiving tofacitinib 2 mg, 5 mg, and 15 mg BID, respect-
ively, had B cell counts above the normal range, compared
with one patient (3.0%) in the placebo group.
Effects on natural killer cells
Treatment with tofacitinib resulted in dose-dependent
percentage reductions from baseline in median NK cell
count at Week 4. At Week 12 the median NK cell count
reduced further in the tofacitinib 2 mg BID group,unts, CMV and EBV DNA count at baseline
Tofacitinib 2 mg BID
(n = 49)
Tofacitinib 5 mg BID
(n = 49)
Tofacitinib 15 mg BID
(n = 49)
45.7 (13.8) 44.0 (12.6) 43.6 (15.6)
29 (59.2) 29 (59.2) 31 (63.2)
36 (73.5) 42 (85.7) 40 (81.6)
89.6 (23.0) 92.2 (23.5) 93.1 (29.7)
21.5 (6.7) 21.2 (8.1) 22.6 (10.3)
29.8 (13.4) 30.1 (17.0) 31.9 (18.8)
8 (16.3) 11 (22.4) 9 (18.8)
39 (79.6) 33 (67.3) 33 (68.8)
2 (4.1) 5 (10.2) 6 (12.5)
1115 (894, 1455) 1206 (1047, 1578) 1162 (935, 1510)
730 (572, 931) 868 (637, 998) 744 (597, 950)
331 (246, 498) 392 (264, 501) 386 (292, 539)
241 (136, 322) 198 (163, 300) 247 (143, 343)
135 (91, 214) 130 (95, 207) 152 (97, 216)
0 (0.00, 0.00) 0 (0.00, 0.00) 0 (0.00, 0.00)
0 (0.00, 0.95) 0 (0.00, 1.00) 0 (0.00, 0.85)
2.54 (1.13, 7.79) 1.92 (1.02, 5.84) 3.14 (0.92, 7.86)
ctive protein; DNA, deoxyribonucleic acid; EBV, Epstein-Barr virus; n, number;
al Assessment (scored on a five-point severity scale); Q, quartile;
Table 2 Change from baseline in lymphocyte sub-populations, EBV and CMV DNA counts, and CRPa
Median percent change in lymphocyte sub-population cell counts, cells/mm3 (Q25, Q75)
Time point Placebo Tofacitinib Tofacitinib Tofacitinib
2 mg BID 5 mg BID 15 mg BID
T (CD3+) Week 4 −0.39 (−14.03, 9.75) 4.79 (−7.45, 17.57) 6.36 (−4.05, 24.24) 8.38 (−9.07, 42.80)
Week 12 2.28 (−8.31, 11.10) 0.10 (−17.18, 15.87) 3.73 (−11.75, 17.54) 0.65 (−23.86, 17.64)
TH (CD3
+/CD4+) Week 4 −0.14 (−10.71, 12.20) 5.52 (−6.73, 18.12) 9.56 (0, 30.24) 15.09 (−5.39, 56.12)
Week 12 0.89 (−7.00, 15.95) −0.90 (−12.29, 15.42) 3.82 (−9.54, 17.99) −0.82 (−22.29, 32.57)
TC (CD3
+/CD8+) Week 4 −4.79 (−12.42, 15.01) 5.13 (−13.33, 19.62) 0.29 (−9.45, 27.35) −0.23 (−19.05, 47.92)
Week 12 3.74 (−11.43, 18.42) −5.58 (−16.27, 11.29) −1.48 (−12.46, 14.07) −0.33 (−28.53, 24.61)
B (CD19+) Week 4 −6.87 (−19.05, 11.40) 23.88 (6.60, 43.13) 45.17 (16.28, 56.84) 67.90 (32.64, 103.79)
Week 12 −0.67 (−12.93, 18.09) 18.03 (0.94, 47.37) 35.32 (9.66, 66.32) 42.86 (16.74, 67.50)
NK (CD16+/CD56+) Week 4 0 (−27.68, 37.60) −10.94 (−28.17, 8.28) −26.11 (−46.71, 4.35) −40.80 (−52.50, −10.06)
Week 12 13.87 (−21.43, 26.67) −20.00 (−34.17, 3.97) −22.76 (−51.38, −1.59) −34.31 (−57.07, −16.57)
Median change in viral load, copies/500 ng total DNA (Q25, Q75)
CMV Week 4 0 (0.00, 0.00) 0 (0.00, 0.00) 0 (0.00, 0.00) 0 (0.00, 0.00)
Week 8 0 (0.00, 0.00) 0 (0.00, 0.00) 0 (0.00, 0.00) 0 (0.00, 0.90)
Week 12 0 (0.00, 0.00) 0 (0.00, 0.00) 0 (0.00, 0.00) 0 (0.00, 0.00)
EBV Week 12 0 (−1.10, 0.00) 0 (0.00, 1.25) 0 (0.00, 0.60) 0.70 (0.00, 2.90)
Median percent change in CRP, % (Q25, Q75)
CRP Week 12 9.42 (−52.41, 61.08) −24.71 (−47.43, 5.49) −36.31 (−74.62, 5.49) −69.17 (−82.20, −34.38)
aSafety set, no imputation.
B, B cells; BID, twice daily; CMV, cytomegalovirus; CRP, C-reactive protein; DNA, deoxyribonucleic acid; EBV, Epstein-Barr virus; NK, natural killer cells; Q, quartile; T,
total T cells; TH, T helper cells; TC, cytotoxic T cells.
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increased in the tofacitinib 15 mg BID group (Table 2,
Figure 1).
Changes in C-reactive protein levels
Median CRP values at baseline are shown in Table 1. At
Week 12, there were dose-dependent percentage reduc-
tions from baseline in median CRP levels in the tofaciti-
nib groups, whereas CRP increased in the placebo group
(Table 2).
Cytomegalovirus and Epstein-Barr virus DNA
The median (quartile [Q]25, Q75) CMV viral load at
baseline was 0 copies/500 ng total DNA (0.0, 0.0) in all
groups. The median change from baseline in CMV DNA
was 0 copies/500 ng total DNA at Week 4, Week 8, and
Week 12 (the Q25 and Q75 were 0.0 for all groups and
time points except for the tofacitinib 15 mg BID group
at Week 8, in which the Q75 value was 0.9) (Table 2,
Figure 2).
CMV DNA was detected in three patients at baseline:
one each in the placebo, tofacitinib 2 mg, and tofacitinib
5 mg BID groups. In all three patients, the CMV viral
load was <1 copy/500 ng total DNA. Only one patient, a
78-year-old white male receiving tofacitinib 15 mg BID,
had post-baseline incidences of CMV DNA >10 copies/500 ng total DNA, which were as follows. This patient had
a positive test for CMV on Day 57 (150 copies/500 ng
total DNA), which was reported as a mild adverse event.
He reported no other adverse signs or symptoms at this
time and continued study treatment. CMV levels subse-
quently reduced to 92 copies/500 ng total DNA at Day 70
while on treatment. Once the initial positive test was
relayed to the investigator site, study treatment was dis-
continued on Day 86, and on Day 87 his CMV level was
19 copies/500 ng total DNA. The event subsequently re-
solved. Another patient had a single incidence of CMV
DNA ≥5 copies/500 ng total DNA. This patient received
tofacitinib 15 mg BID, and had a CMV viral load of 7 cop-
ies/500 ng total DNA at Week 8, with no adverse events
reported. The patient discontinued treatment and the ele-
vated CMV levels resolved.
No comparison of baseline vs post-baseline CMV de-
tectability was possible for patients with detectable CMV
at baseline, due to limited sample size (Tables 1 and 3).
In patients with undetectable CMV at baseline, tofaciti-
nib was associated with detectable CMV at one or more
time points post-baseline (Chi-squared test, p = 0.0001;
Table 3). When individual tofacitinib groups were evalu-
ated, the number of patients in whom CMV became de-
tectable post-baseline was significant in the tofacitinib
15 mg BID group only (p = 0.004 vs placebo).
Figure 1 Median percent change from baseline in lymphocyte sub-population cell counts. The horizontal line within each box represents median,
with the bottom and top of each box representing the 1st and 3rd quartiles, respectively. Error bars represent minimum and maximum values.
B, B cells; BID, twice daily; NK, natural killer cells; T, total T cells; TH, T helper cells; TC, cytotoxic T cells.
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Figure 2 Viral DNA count at baseline and post-baseline in patients receiving tofacitinib or placebo. For: a) CMV and b) EBV; each data point
represents a measurement for an individual patient. BID, twice daily; CMV, cytomegalovirus; EBV, Epstein-Barr virus.
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Table 3 Changes from baseline in CMV and EBV viral load in patients receiving placebo or tofacitinib 2 mg, 5 mg or
15 mg BID












Placebo 49 (46) 44 (95.7) 2 (4.3) N/A 0.0001
Tofacitinib 2 mg BID 48 (46) 41 (89.1) 5 (10.9) 0.2381
Tofacitinib 5 mg BID 48 (45) 42 (93.3) 3 (6.7) 0.6274
Tofacitinib 15 mg BID 49 (48) 32 (66.7) 16 (33.3) 0.0004








Placebo 1 (1) 0 (0) 1 (100.0) N/A –
Tofacitinib 2 mg BID 1 (1) 0 (0) 1 (100.0) –
Tofacitinib 5 mg BID 1 (1) 0 (0) 1 (100.0) –
Tofacitinib 15 mg BID 0 (0) 0 (0) 0 (0) –








Placebo 28 (20) 18 (90.0) 2 (10.0) N/A 0.0122
Tofacitinib 2 mg BID 30 (25) 14 (56.0) 11 (44.0) 0.0124
Tofacitinib 5 mg BID 26 (19) 15 (78.9) 4 (21.1) 0.3390
Tofacitinib 15 mg BID 31 (28) 14 (50.0) 14 (50.0) 0.0038








Placebo 21 (19) 9 (47.4) 10 (52.6) N/A 0.1299
Tofacitinib 2 mg BID 18 (13) 9 (69.2) 4 (30.8) 0.2208
Tofacitinib 5 mg BID 21 (14) 10 (71.4) 4 (28.6) 0.1669
Tofacitinib 15 mg BID 17 (14) 12 (85.7) 2 (14.3) 0.0236
aA statistical comparison of change in CMV detectability from detectable at baseline to undetectable post-baseline was not possible due to limited sample size.
BID, twice daily; CMV, cytomegalovirus; EBV, Epstein-Barr virus; N, number of patients with baseline values; n, number of patients with baseline and post-baseline
values; N/A, not applicable.
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0.0 copies/500 ng total DNA (0.0, 1.3) in all groups
(Table 1). Twelve patients had baseline EBV DNA
≥5 copies/500 ng total DNA: three receiving placebo,
and three, four, and two patients receiving tofacitinib
2 mg, 5 mg, and 15 mg BID, respectively. Of these, seven
patients (three in the placebo group, and two each in the
tofacitinib 5 mg and 15 mg BID groups) had EBV DNA
>10 copies/500 ng total DNA. The highest EBV DNA
value at baseline (86 copies/500 ng total DNA) was re-
ported for a patient in the tofacitinib 5 mg BID group.
This patient had a mild, upper respiratory tract infection
at study entry, which began 12 days before treatment
and resolved on Day 15.
At Week 12, the median (Q25, Q75) change from
baseline in EBV viral load was 0 (–1.1, 1.3) for all groups
except for the tofacitinib 15 mg BID group, in which the
median EBV DNA count increased by 0.7 copies/500 ng
total DNA (0.0, 2.9) (Table 2). Twenty-two patients had
EBV DNA ≥5 copies/500 ng total DNA at Week 12:three receiving placebo, and five, five, and nine patients
receiving tofacitinib 2 mg, 5 mg, and 15 mg BID, re-
spectively. Of these, nine patients (two each in the pla-
cebo, tofacitinib 2 mg, and 5 mg BID groups, and three
in the tofacitinib 15 mg BID group) had EBV DNA
>10 copies/500 ng total DNA. The highest EBV DNA
values at Week 12 were reported for a patient receiving
tofacitinib 2 mg BID and a patient receiving tofacitinib
15 mg BID (33 copies and 36 copies/500 ng total DNA,
respectively). Both had EBV levels ≥5 copies/500 ng total
DNA at baseline. The patient with EBV levels of 33 cop-
ies/500 ng total DNA had adverse events of increased
low-density lipoprotein and increased blood cholesterol
reported at that time point. The patient with EBV DNA
36 copies/500 ng total DNA had no adverse events
reported.
Overall, in patients with undetectable EBV at baseline,
tofacitinib was associated with detectable EBV at Week
12 (Chi-squared test, p = 0.0122). The number of pa-
tients in whom EBV became detectable post-baseline
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(p = 0.0124) and 15 mg BID (p = 0.0038) groups (Table 3).
However, there was also a significant proportion of
patients in the tofacitinib 15 mg BID group who had de-
tectable EBV at baseline and undetectable EBV at Week
12 (p = 0.0236 vs placebo) (Table 3).
Correlation analyses
Spearman’s rank correlation coefficient (rho) analyses of
pooled patient data showed that EBV viral load, but not
CMV viral load, was weakly correlated with larger
changes in total T cell, TH cell, TC cell, and B cell counts
after 12 weeks of treatment (rho: 0.19, 0.20, 0.17, and
0.25, respectively). Changes in CRP level showed a weak
inverse correlation with larger changes in total T cell, TH
cell, TC cell, and B cell counts after 12 weeks of treat-
ment (rho: −0.28, −0.26, −0.20, and −0.40, respectively)
(Table 4).
Potential correlations between tofacitinib dose, lympho-
cyte sub-population cell counts, CMV and EBV viral load,
and CRP level were evaluated. Multivariate analyses using
a general linear model detected no correlation between
change in CMV or EBV viral load and lymphocyte sub-
populations or dose of tofacitinib (Table 5). However,
there was strong and significant correlation between
change in CRP levels and change in TC cell count
(p = 0.043) or dose of tofacitinib (p = 0.026) (Table 5).
Discussion
Clinical data describing the impact of immunosuppres-
sive therapies on the overall risk of infection and serious
infection are limited in patients with psoriasis compared
with rheumatoid arthritis (RA). However, there is emer-
ging evidence to suggest that the infection risk associ-
ated with various therapies used in the RA setting may
not be replicated in the psoriasis setting [22-24]. More-
over, effects of psoriasis therapies on immunosurveil-
lance may vary according to the mechanism of action
for each agent.
In this investigation, there was no clinically significant
relationship between changes in CMV or EBV viral load
and changes in lymphocyte sub-populations. Minimal
and transient effects on T cell counts were identified inTable 4 Spearman’s rank correlation coefficients between cha
or CRP level, and change in lymphocyte sub-populations
Change in outcome variables, rho
(p value)
Lymphocyte sub-populations
T (CD3+) TH (CD3
+/
CMV viral load, copies/500 ng total DNA −0.0499 (0.5742) −0.0889 (0
EBV viral load, copies/500 ng total DNA 0.1872 (0.0351) 0.1970 (0.0
CRP level, mg/L −0.2832 (0.0008) −0.2644 (0
The correlation analyses presented above were performed using pooled data from
B, B cells; CMV, cytomegalovirus; CRP, C-reactive protein; DNA, deoxyribonucleic acid; E
coefficient; T, total T cells; TH, T helper cells; TC, cytotoxic T cells.patients receiving tofacitinib, which may be related to
modulation of cytokines, resultant modulation of adhesion
molecules, and consequent trafficking of T cells. This is
supported by dose-dependent percent changes from base-
line in median total T cell (CD3+) count at Week 4, which
appeared to normalize across all doses by Week 12. Dose-
dependent percentage changes in median B cell and NK
cell count were observed with tofacitinib treatment, with
B cell count increased from baseline and NK cell count
decreased from baseline at Week 12. Overall, changes in
lymphocyte sub-populations observed in this study appear
consistent with observations in patients receiving tofaciti-
nib for RA [25].
TH cell counts correlated well with total lymphocyte
counts over time, suggesting that tofacitinib does not
change the TH cell distribution. A TH cell count
<200 cells/mm3, which is a known risk factor for oppor-
tunistic infections in patients with human immunodefi-
ciency virus (HIV) [26] was not observed in any patient
in the present study. In addition, excluding those pa-
tients with a TH cell count <500 cells/mm
3 at baseline,
fewer than 5% of patients in each group had a post-
baseline TH cell count <500 cells/mm
3. In other settings
in which patients may be immunocompromised, includ-
ing bone marrow transplantation, a significant correl-
ation with the occurrence of opportunistic infection has
been observed only in patients with a TH cell count
below 115 cells/mm3 [27,28]. Based on data collected dur-
ing this study, there is no need to routinely monitor levels
of lymphocyte sub-populations in patients receiving tofa-
citinib therapy for plaque psoriasis. However, longer-term
observation would be needed to confirm these findings.
In the present study, mean baseline CRP levels for each
group ranged from 3.10 to 5.47 mg/L, which is above the
3.0 mg/L threshold for high relative risk of cardiovascular
disease [29]. Tofacitinib therapy was associated with dose-
dependent reductions in CRP at Week 12, reflecting the
anti-inflammatory activity of tofacitinib. This is supported
by the significant correlation between tofacitinib dose and
changes in CRP. Furthermore, the observed, transient in-
crease from baseline in peripheral lymphocytes in patients
receiving tofacitinib, and the inverse correlation between
changes in CRP level and larger changes in T cell, TH cell,nge from baseline to week 12 in CMV or EBV viral load,
CD4+) TC (CD3
+/CD8+) B (CD19+) NK (CD16+/CD56+)
.3164) 0.0020 (0.9817) −0.0530 (0.5505) −0.0148 (0.8674)
264) 0.1711 (0.0544) 0.2491 (0.0047) 0.0033 (0.9709)
.0017) −0.2009 (0.0181) −0.3996 (0.0000) 0.0699 (0.4152)
the placebo and tofacitinib groups.
BV, Epstein-Barr virus; NK, natural killer cells; rho, Spearman’s rank correlation
Table 5 Correlation analysis results from a general linear model with change from baseline to week 12 in CMV or EBV
viral load or change in CRP level as the response variable, and dose of tofacitinib and change in lymphocyte
sub-populations as explanatory variables




T (CD3+) TH (CD3
+/CD4+) TC (CD3
+/CD8+) B (CD19+) NK (CD16+/CD56+)
CMV viral load, copies/500 ng total DNA df 3 1 1 1 1 1
F value 1.26 0.14 0.04 0.68 0.00 0.03
p value 0.2926 0.7047 0.8411 0.4112 0.9925 0.8592
EBV viral load, copies/500 ng total DNA df 3 1 1 1 1 1
F value 0.50 0.54 1.69 0.11 0.02 0.57
p value 0.6807 0.4627 0.1955 0.7430 0.8906 0.4501
CRP level, mg/L df 3 1 1 1 1 1
F value 3.18 1.45 1.84 4.18 0.11 1.83
p value 0.0262 0.2315 0.1775 0.0430 0.7450 0.1784
aDoses of tofacitinib considered in this analysis were 0 mg, 2 mg, 5 mg, and 15 mg BID.
B, B cells; BID, twice daily; CMV, cytomegalovirus; CRP, C-reactive protein; df, degrees of freedom; DNA, deoxyribonucleic acid; EBV, Epstein-Barr virus; NK, natural
killer cells; T, total T cells; TH, T helper cells; TC, cytotoxic T cells.
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consistent with the recruitment of lymphocytes to sites of
inflammation and release of lymphocytes as inflammation
resolves.
There is published evidence to suggest an association
between active plaque psoriasis and reactivation of
CMV, with one study identifying a correlation between
psoriasis disease activity in CMV seropositive patients
and severity of CMV-antigenemia [30]. In the present
study, there was an overall association between tofaciti-
nib and post-baseline detectability of CMV and EBV
DNA, and significant changes in CMV and EBV detect-
ability in the tofacitinib 2 mg and 15 mg BID groups (vs
placebo). When considered alongside viral load measure-
ments for individual patients, in most cases, changes in
CMV and EBV detectability are likely to reflect only sub-
tle differences in viral load. Indeed, a multivariate ana-
lysis showed no correlation between viral load and dose
of tofacitinib. Considering the important role of T cells
and NK cells in the response to viral infection [31,32],
this finding implies that the modest changes in lympho-
cyte sub-populations observed during 12 weeks of tofaci-
tinib therapy did not translate into clinically significant
changes in effective immunosurveillance. Moreover, the
lack of changes in viral load also suggests that T cell
function, critical for control of viral infections [33], is
preserved in patients treated with tofacitinib, at least
over the course of 12 weeks. This conclusion is sup-
ported by the case of one patient with a treatment-
emergent adverse event of elevated CMV, whose CMV
levels reduced before stopping treatment and who did
not develop any clinical symptoms.
In the HIV setting, a CMV viral load of >200 copies/mL
predicts the future occurrence of CMV end organdisease [34]. There is no single treatment threshold for
CMV in the transplant setting. However, a CMV viral
load cut-off of 5000 copies/mL for pre-emptive therapy
was described in a recent study investigating CMV re-
activation in 161 liver transplant patients [35]. In an-
other study involving 28 liver transplant patients, the
median viral load associated with symptomatic CMV
disease was 230,000 copies/mL [36]. These levels are
substantially in excess of the maximum CMV level re-
ported in any patient in this study.
There are few published studies describing the effects
of other therapies for RA or psoriasis on CMV or EBV
viral load. A study with 62 patients, aged 2–28 years, re-
ceiving biologic (including infliximab and etanercept) or
nonbiologic treatment for juvenile RA, Crohn’s disease,
or ulcerative rectocolitis detected CMV DNA in 1.6% of
patients and EBV in 4.8% of patients [37]. All but one
patient with detectable CMV or EBV had received non-
biologic therapy in the preceding year. Neither CMV
nor EBV DNA was detected in the control group, which
comprised 62 healthy volunteers. However, the extent to
which viral load was related to the underlying disease or
the treatment received was unclear [37]. A study of EBV
viral load in 122 patients receiving biologic agents, in-
cluding TNFi, for inflammatory arthritis found that 90%
of patients receiving active treatment (and 98% of
biologic-naïve controls) had a positive antibody test for
EBV during treatment, although subsequent PCR testing
revealed no evidence of viral activation [38]. In addition,
Niemann and colleagues detected no EBV DNA in 26
patients with psoriasis who received at least eight weeks
of treatment with various nonbiologic and biologic
agents (methotrexate, cyclosporine, etanercept, or alefa-
cept) [39]. It should be noted that our investigation, and
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sured viral load in patients who were asymptomatic for
infection with CMV or EBV. In other indications where
immunosuppressive therapy is used, such as RA and
transplantation, an associated risk of viral infections has
been observed [40], although the duration of treatment
in that study was substantially longer than the 12-week
duration of tofacitinib therapy in this study. Thus, the
available evidence suggests that, while CMV or EBV
DNA may become detectable in some patients during
treatment with biologic or nonbiologic therapy for in-
flammatory diseases such as plaque psoriasis, viral re-
activation and symptomatic clinical infections are rare.
Potential limitations of this analysis were the duration
of exposure to tofacitinib (12 weeks) and the use of
lymphocyte subsets (CD4 and CD8) as surrogates of
virus-specific CD4+ and CD8+ cells. While no effect of
tofacitinib exposure on viral load was observed over the
12-week study period, one cannot be certain that such
an effect would not be observed over a more prolonged
period of exposure. With regard to lymphocyte subsets
it is possible, albeit unlikely, that tofacitinib treatment
could affect the number or function of virus-specific
cells without markedly affecting the total number of
cells. The absence of an observed increase in viral load
suggests that the number and function of these virus-
specific cells was sufficient to control viral replication.
Conclusions
In patients with psoriasis, 12 weeks of tofacitinib treat-
ment had no clinically significant effects on CMV or EBV
viral load, suggesting that lymphocyte sub-populations
critical to the response to chronic viral infections and viral
reactivation were not significantly affected. Replication of
these findings during long-term use of tofacitinib will
allow confirmation of this observation.
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